<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id>
      <journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id>
      <journal-title-group>
        <journal-title>Indian Journal of Ophthalmology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0301-4738</issn>
      <issn pub-type="epub">1998-3689</issn>
      <publisher>
        <publisher-name>Medknow Publications</publisher-name>
        <publisher-loc>India</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17951906</article-id>
      <article-id pub-id-type="pmc">2635977</article-id>
      <article-id pub-id-type="publisher-id">IndianJOphthalmol_2007_55_6_460_36484</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Raghuram</surname>
            <given-names>A</given-names>
          </name>
          <degrees>DNB, FRCS</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Saravanan</surname>
            <given-names>VR</given-names>
          </name>
          <degrees>DNB, FRCS</degrees>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Narendran</surname>
            <given-names>V</given-names>
          </name>
          <degrees>DNB</degrees>
        </contrib>
        <aff>
Retina and Vitreous Services, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Avinashi Road, Coimbatore - 641 014, Tamil Nadu, India</aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">Correspondence to Dr. A Raghuram, Vitreo-Retinal services, Aravind Eye Hospital, Avinashi Road, Civil Aerodrome Post, Coimbatore - 641 014, Tamil Nadu, India. Email:<email>nrkavi@yahoo.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2007</year>
      </pub-date>
      <volume>55</volume>
      <issue>6</issue>
      <fpage>460</fpage>
      <lpage>462</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>9</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>12</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Indian Journal of Ophthalmology</copyright-statement>
        <copyright-year>2007</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Intracameral injection of bevacizumab (Avastin) helped in the successful regression of an anterior chamber neovascular membrane in a painful blind eye. The effect was persistent even after six months of follow-up. This is the first report on intracameral administration of bevacizumab with six months of follow-up.</p>
      </abstract>
      <kwd-group>
        <kwd>Avastin</kwd>
        <kwd>bevacizumab</kwd>
        <kwd>intracameral injection
</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Intravitreal administration of bevacizumab (Avastin, Genetech, Inc, San Francisco, CA), a humanized monoclonal antibody to vascular endothelial growth factor (VEGF) has recently been reported to be of benefit in choroidal neovascular membrane,<xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref2">2</xref>  retinal neovascularization in proliferative diabetic retinopathy<xref ref-type="bibr" rid="ref3">3</xref> and iris neovascularization.<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref>  We observed rapid resolution of anterior chamber neovascularization following intracameral injection of bevacizumab in a patient with painful blind eye.</p>
    <sec sec-type="">
      <title>Case Report</title>
      <p>A 31-year-old woman presented with pain and redness in her left eye. Visual acuity in the left eye was no perception of light and 20/20 in the right eye. The right eye was normal. The left eye was blind for the past 20 years following an injury. On examination the left eye showed circumcorneal congestion, anterior chamber cells and flare, peripheral anterior synechiae, ectropion uveae and an active fibrovascular membrane <xref ref-type="fig" rid="F1">[Fig. 1A]</xref> on the iris and over the partially absorbed cataractous lens. The intraocular pressure was 6 mmHg. Contact B-scan ultrasonography revealed a total retinal detachment. Earlier the patient was treated with long-term topical steroids and cycloplegics with no significant relief of symptoms. So the patient was offered an off-label intracameral injection of 1.00 mg of bevacizumab (0.04 ml of Avastin, Genentech, INC, San Francisco, CA at a concentration of 25 mg /ml). The consent of the patient was obtained after explaining the risks and benefits of the treatment. One week following the intracameral injection the circumcorneal congestion disappeared and the anterior chamber inflammation decreased and there was dramatic regression of neovascularization <xref ref-type="fig" rid="F1">[Fig. 1B]</xref>. The post injection intraocular pressure was 8 mmHg on day one and after one week. After six months this response to treatment sustained and the patient remained symptom-free <xref ref-type="fig" rid="F1">[Fig. 1C]</xref>.</p>
    </sec>
    <sec sec-type="">
      <title>Discussion</title>
      <p>Genentech (San Francisco, CA) developed a monoclonal antibody against VEGF that was tested as a cancer therapy with the idea that reducing the vascular supply to a tumor may inhibit growth of the cancer. VEGF is a protein and is the most important growth factor for neovascularization in a variety of tissues including the eye.</p>
      <p>Hypoxia stimulates the secretion of VEGF in retinal pigment epithelial cells<xref ref-type="bibr" rid="ref6">6</xref>  and VEGF production increases with neovascularization of the iris in primates.<xref ref-type="bibr" rid="ref7">7</xref>  In retinal detachment there is alteration in retinal perfusion arising from separation of the choroidal blood supply from the retinal pigment epithelium and can result in relative retinal ischemia. This ischemia stimulates the production of VEGF in retinal pericytes, endothelial cells, the retinal pigment epithelium and possibly other cell types.<xref ref-type="bibr" rid="ref8">8</xref>  The VEGF is either bound to the cell-surface or basement-membrane proteoglycans containing heparin (VEGF189, 286) or freely diffusible within the vitreous cavity (VEGF121, 165).<xref ref-type="bibr" rid="ref9">9</xref>  Diffusible VEGF follows its concentration gradient from the vitreous to the anterior segment and is cleared through the trabecular meshwork. Neovascularization can arise anywhere along this course. Inhibitions by means of antibody, antibody fragment or aptamer binding are strategies used in medicine to reduce the effects of VEGF in a variety of diseases. Our patient received 1 mg of bevacizumab, an antibody to VEGF, as an intracameral injection. The complete regression of neovascular membrane was noted after a week. We expected recurrence of neovascularization after some time, but there was no recurrence even after six months. Lloyd Paul Aiello and associates have mentioned in their article on VEGF in ocular fluid that "cell death without ischemia would have less vasoproliferative potential, since increased VEGF production would not be possible".<xref ref-type="bibr" rid="ref8">8</xref>  In our patient the eye is going for phthisical state and maybe the cells responsible for the production of VEGF are dying without ischemia. The existing load of VEGF was taken care of by the therapy and there was no new VEGF production. Probably this is the reason why the patient did not have recurrence.</p>
      <p>Regression of retinal and iris neovascularization after intravitreal injection of bevacizumab in human eyes has been reported.<xref ref-type="bibr" rid="ref3">3</xref>,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref5">5</xref> Although there is one report<xref ref-type="bibr" rid="ref10">10</xref> on intracameral administration of bevacizumab with one month follow-up, we believe that this is the first report on intracameral administration of bevacizumab with six months of follow-up. This case clearly demonstrates the dramatic effect of bevacizumab on ocular neovascularization, which might help in widening the spectrum of bevacizumab usage in ocular diseases.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Dr. Richard F Spaide of Vitreous-Retina-Macula consultants of New York, NY, USA.</p>
    </ack>
    <ref-list>
      <ref id="ref1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenfeld</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Moshfegh</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Puliafito</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Optical Coherence Tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age related macular degeneration</article-title>
          <source>Ophthalmic Surg Lasers Imaging</source>
          <year>2005</year>
          <volume>36</volume>
          <fpage>331</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">16156152</pub-id>
        </element-citation>
      </ref>
      <ref id="ref2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Avery</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Pieramjci</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Rabena</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Castellarin</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Nasir</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Giust</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration</article-title>
          <source>Ophthalmology</source>
          <year>2006</year>
          <volume>113</volume>
          <fpage>363</fpage>
          <lpage>72</lpage>
          <pub-id pub-id-type="pmid">16458968</pub-id>
        </element-citation>
      </ref>
      <ref id="ref3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spaide</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>YL</given-names>
            </name>
          </person-group>
          <article-title>Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>275</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">16508426</pub-id>
        </element-citation>
      </ref>
      <ref id="ref4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Avery</surname>
              <given-names>RL</given-names>
            </name>
          </person-group>
          <article-title>Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>352</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="pmid">16508438</pub-id>
        </element-citation>
      </ref>
      <ref id="ref5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davidorf</surname>
              <given-names>FH</given-names>
            </name>
            <name>
              <surname>Mouser</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Derick</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection</article-title>
          <source>Retina</source>
          <year>2006</year>
          <volume>26</volume>
          <fpage>354</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">16508439</pub-id>
        </element-citation>
      </ref>
      <ref id="ref6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shima</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Adamis</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Yeo</surname>
              <given-names>TK</given-names>
            </name>
          </person-group>
          <article-title>Hypoxic regulation of vascular permeability factor (vascular endothelial growth factor) mRNA and protein secretion by human retinal pigment epithelial cells</article-title>
          <source>Invest Ophthalmol Vis Sci</source>
          <year>1993</year>
          <volume>34</volume>
          <fpage>900</fpage>
        </element-citation>
      </ref>
      <ref id="ref7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adamis</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>O&#x2032;Reilly</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Vascular permeability factor (vascular endothelial growth factor) is produced in the retina and elevated levels are present in the aqueous humor of patients with iris neovascularization</article-title>
          <source>Invest Ophthalmol Vis Sci</source>
          <year>1993</year>
          <volume>34</volume>
          <fpage>1440</fpage>
        </element-citation>
      </ref>
      <ref id="ref8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aiello</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Avery</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Arrigg</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Keyt</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Jampel</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>ST</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders</article-title>
          <source>N Engl J Med</source>
          <year>1994</year>
          <volume>331</volume>
          <fpage>1480</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">7526212</pub-id>
        </element-citation>
      </ref>
      <ref id="ref9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Houck</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Leung</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Rowland</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Winer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ferrara</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms</article-title>
          <source>J Biol Chem</source>
          <year>1992</year>
          <volume>267</volume>
          <fpage>26031</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">1464614</pub-id>
        </element-citation>
      </ref>
      <ref id="ref10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grisanti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Biester</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tatar</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Ziemssen</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bartz-Schmidt</surname>
              <given-names>KU</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intracameral bevacizumab for iris rubeosis</article-title>
          <source>Am J Ophthalmol</source>
          <year>2006</year>
          <volume>142</volume>
          <fpage>158</fpage>
          <lpage>60</lpage>
          <pub-id pub-id-type="pmid">16815268</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>(A) Slit-lamp photograph showing circumcorneal congestion and neovascularization over the iris and lens capsule (Black arrow); (B and C) Photographs showing the total regression of neovascularization one week and six months respectively following intracameral injection of bevacizumab (Avastin)</p>
      </caption>
      <alt-text>Figure 1</alt-text>
      <graphic xlink:href="IndianJOphthalmol-55-460-g001"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
